Founded: 1994, QEII created by provincial government order; 1800s, constituent facilities founded as separate entities
Malignant pleural mesothelioma, murine malignant mesothelioma, and clinical trials to test new cancer treatments.
The Queen Elizabeth II is affiliated with the Faculty of Medicine and Health Professions at Dalhousie University in Halifax. Accredited by the Canadian Council on Health Services Accreditation, the center is administratively part of the Capital District Health Authority. The QEII is the largest teaching hospital and adult academic health sciences center in Atlantic Canada. The QEII is composed of 10 buildings located on two sites: the Halifax Infirmary site and the Victoria General site, which houses Thoracic Surgery. Oncological specialists oversee medical residents and students. The QEII offers a variety of cancer care treatment options including surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy, biological therapy or a combination of treatments. The health care team ensures that each patient receives a customized treatment protocol. The Cancer Care program provides an interdisciplinary approach to treating cancer. Satellite oncology clinics at local hospitals allow patients to receive some treatments closer to home. Specialized psychosocial and palliative care oncology teams deal with psychological, emotional, spiritual, social, family and symptom management issues as well as end-of-life. The teams include social workers, spiritual care providers, advanced practice nurses, psychologists, psychiatrists, medical doctors, pharmacists, dietitians, physiotherapists, and occupational therapists. Patients can receive free therapeutic treatments, including reiki, massage therapy, reflexology, healing touch and therapeutic touch in the Sunshine Room in the Victoria Building. Housed in the Dickson Building, the Nova Scotia Cancer Centre is the only comprehensive adult cancer treatment center in Nova Scotia. The Centre for Clinical Research (CCR) is responsible for all research carried out at the QEII. Ongoing clinical trials test new cancer treatments. Research has included the effect of Gefitinib to treat malignant pleural mesothelioma and the early infiltrating interferon-gamma producing NKT cells in murine malignant mesothelioma.